Parkinson’s disease drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Parkinson's Disease Drugs Market

The Parkinson's disease drugs market size was valued at USD 4,500.0 million in 2018, and the market is now projected tgrow from USD 13,580.0 million by 2032, exhibiting a CAGR of 8.2% during the forecast period of 2019-2032.

Hoffmann-La Roche Ltd. and UCB S.A. were the market leaders in 2018 because of the drastic sales of Madopar and Neupro. These collaborations further improved the Parkinson's disease drugs market growth. The third spot is found with Acadia Pharmaceuticals, which landed the position because of the requisites of Nuplazid. Expectedly, the share of Acadia would rise more with the uptake of INBRIJA in FY 2019. Important players outside Acadia include Pfizer, Merck, Teva, Orion Pharma and Lundbeck. Since this therapy has rejuvenated the 2019 fiscal year, therefore, a rise in Acadia's stake would be expected.

In the same year, this market share for decarboxylase inhibitors-cabridopa and levodopa-cumbrance management was 37.8, which can be said tlead. It is now nowadays Levodopa as the most prevailing therapy for Parkinson's disease. An increased clinical trial with the implantation of RYTARY by Impax Laboratories stimulates the Parkinson's disease drugs market share. It is expected tbe the largest CAGR during this timeframe. Consequently, there would be an overall growth in demand around the market.

Comprehensive Analysis of Parkinson's Disease Drugs Market

The Parkinson's disease drugs market and healthcare industry is rising at an exponential rate due tits market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by Drug Class, by Route of Administration and by Distribution Channels. The Drug Class includes, Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor and Catechol-O-Methyltransferase (COMT) Inhibitors. The Route of Administration includes, Oral, Injection and Transdermal. The Distribution Channels includes hospitals and Hospital Pharmacy, Retail Pharmacy and Online Pharmacy.

Europe dominates the global Parkinson’s disease market in terms of maximum revenue of USD 1,540.7 million in 2018 majorly because of amplified incidences of Parkinson’s disease, and enhanced support from the government through government-supported pharmacies. However, better research and development spending and projected approval and launch of some pipeline drug candidates are expected tmove the maximum share of the Parkinson’s disease drugs market tNorth America by the end of 2026.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Pfizer, Inc., Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Orion Pharma, UCB S.A, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc., Impax Laboratories, Inc., Lundbeck A/S and Other players. These market players provide a level-playing competitive landscape.

In May 2021, The U.S. FDA granted investigational new drug designation tPharmaTher for ketamine in LD-induced dyskinesias in Parkinsonian patients. This approval will alsunblock paths for PharmaTher tconduct the phase II clinical trial in treating low-dose Ketamine.

Segmentation Table

Global Parkinson's Disease Drugs Market Scope

By Drug Class

Decarboxylase Inhibitors

Dopamine Agonists

Monoamine Oxidase Type B (MAO-B) Inhibitor

Catechol-O-Methyltransferase (COMT) Inhibitors

Others

By Route of Administration

Oral

Injection

Transdermal

By Distribution Channels

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Geography

North America (USA and Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

Latin America (Brazil, Mexicand Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)